Atlas Trials

Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer

Clinical trial NCT02237690 · COMPLETED

Trial details

NCT number
NCT02237690
Sponsor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Ovarian Cancer
Start date
2014-09-01
Primary completion
2015-08-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.